en · de · es · fr · pt
liraglutide-notes.peptides6908.com › Info › Molecular Background And Receptor Pharmacology — Reference Sheet

Molecular Background And Receptor Pharmacology — Reference Sheet

By Editorial Desk · published 2026-07-14 · last reviewed 2026-08-01 · Info

This is a working overview of aggregation, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Molecular Background and Receptor Pharmacology

The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.

After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.

Tirzepatide 分子背景与靶点

该化合物的名称与结构由国际非专利名称体系统一维持,不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体,而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录,可作为分析检测和质量研究的参照。

Tirzepatide at a glance

PropertyValueNotes
Molecular formulaC225H348N48O68Approximate composition of the free peptide
Molecular weightApproximately 4813 DaCalculated for the free base
Structural classSynthetic linear peptide39 residues with modified backbone
SolubilitySoluble in water and polar solventsBehavior of the lyophilized solid
Typical storage temperature-20 degrees Celsius or belowSolid form, protected from light

Dual Incretin Receptor Agonism

Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.

Related pages on this site

Analytical Characterization and Storage Stability

Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.

Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.

储存处理与检测方法

质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持,单次测定不足以判定批次的稳定性。实验室之间方法转移时,色谱柱品牌与梯度差异常导致保留时间漂移,因此方法验证十分必要。

固体状态的 tirzepatide 通常以冻干粉形式保存,推荐在低温、避光、干燥条件下存放,常见区间为 2 至 8 摄氏度,长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出,从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。

溶解操作一般使用注射用水或适宜的水性缓冲液,必要时加入少量助溶剂以改善溶解速度,但应避免剧烈涡旋振荡,因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态,具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分,则取决于用途是否为多次取样。

Supporting material

=== Polonnaruwa === On 29 December 2012 a green fireball was observed in Polonnaruwa, Sri Lanka. It disintegrated into fragments that fell to the Earth near the villages of Aralaganwila and Dimbulagala and in a rice field near Dalukkane. Rock samples were submitted to the Medical Research Institute of the Ministry of Health in Colombo. The rocks were sent to the University of Cardiff in Wales for analysis, where Chandra Wickramasinghe's team analyzed them and claimed that they contained extraterrestrial diatoms. From January to March 2013, five papers were published in the fringe Journal of Cosmology outlining various results from teams in the United Kingdom, United States and Germany. However, independent experts in meteoritics stated that the object analyzed by Wickramasinghe's team was of terrestrial origin, a fulgurite created by lightning strikes on Earth. Experts in diatoms complemented the statement, saying that the organisms found in the rock represented a wide range of extant terrestrial taxa, confirming their earthly origin. Wickramasinghe and collaborators responded, using X-ray diffraction, oxygen isotope analysis, and scanning electron microscope observations, in a March 2013 paper asserting that the rocks they found were indeed meteorites, instead of being created by lightning strikes on Earth as stated by scientists from the University of Peradeniya. However, these claims were also criticised for not providing evidence that the rocks were actually meteorites.

=== Criteria === Diabetic ketoacidosis is distinguished from other diabetic emergencies by the presence of large amounts of ketones in blood and urine, and marked metabolic acidosis. Hyperosmolar hyperglycemic state (HHS, sometimes labeled "hyperosmolar non-ketotic state" or HONK) is much more common in type 2 diabetes and features increased plasma osmolarity (above 320 mosm/kg) due to profound dehydration and concentration of the blood; mild acidosis and ketonemia may occur in this state, but not to the extent observed in DKA. There is a degree of overlap between DKA and HHS, as in DKA the osmolarity may also be increased. Ketoacidosis is not always the result of diabetes. It may also result from alcohol excess and from starvation; in both states the glucose level is normal or low. Metabolic acidosis may occur in people with diabetes for other reasons, such as poisoning with ethylene glycol or paraldehyde. The American Diabetes Association categorizes DKA in adults into one of three stages of severity:

This suggests BDNF is not only capable of initiating synapse formation through its effects on NMDA receptor activity, but it can also support the regular every-day signaling necessary for stable memory function. BDNF is also required for stabilizing actin polymerization in spines through triggering the activation of the WAVE regulatory complex.

Sources: en.wikipedia.org

Notes from published material

Tris, or tris(hydroxymethyl)aminomethane, or known during medical use as tromethamine or THAM, is an organic compound with the formula (HOCH2)3CNH2. It is extensively used in biochemistry and molecular biology as a component of buffer solutions such as in TAE and TBE buffers, especially for solutions of nucleic acids. It contains a primary amine and thus undergoes the reactions associated with typical amines, e.g., condensations with aldehydes. Tris also complexes with metal ions in solution. In medicine, tris (known as tromethamine) is occasionally used as a drug, given in intensive care for its properties as a buffer for the treatment of severe metabolic acidosis in specific circumstances. Some medications are formulated as the "tromethamine salt" including Hemabate (carboprost as trometamol salt), and "ketorolac trometamol". In 2023 a strain of Pseudomonas hunanensis was found to be able to degrade TRIS buffer. Since Tris's pKa is more strongly temperature dependent, its use is not recommended in biochemical applications requiring consistent pH over a range of temperatures. Moreover, the temperature dependence of the pKa (and in turn buffer solution pH) makes pH adjustment difficult. (E.g., the 'room temperature' pH adjustment would not translate to 'measurement conditions' pH, unless care is taken to calculate the effect of temperature, see below.)

In 1981 Channon left Guy's Hospital to continue his work with Drs Martin Hartog and Richard Paisey at the Bristol Royal Infirmary. Channon then developed the miniature Portaject device. Unlike the Multiject the Portaject is designed to be worn. It has the capacity for sufficient insulin for 24 hours (at the time insulin had to be refrigerated; at room or body temperature it would become unusable after 24 hours). Channon self-funded the design and fabrication work through his company Channon Medical Ltd. He filed a patent for the Portaject in 1988 but subsequently withdrew the application, choosing instead to donate his research to the field. Clinical trials at the BRI were supported by a small grant of £4,500 from the National Medical Research fund. Dr Hartog attests that "Portaject was the first device that allowed convenient repeated subcutaneous injections of insulin and led to the Novopen. Administration of insulin in this way resulted in a much improved control of the patient's diabetes and, consequently, to a considerably improved prognosis overall". Dr Paisey recalls that clinical trials were conducted with 20 patients and that "one of them continued for 20 years with the same device and achieved good glycemic control. He also designed and manufactured a belt to house the pump". Another long term user, Stephen Dixon, wrote to Channon "Thanks so much for doing what you did. You truly helped transform millions of lives, including mine". In 1989 Channon developed a simple device for protecting, lubricating and sterilizing a hypodermic needle.

Under the law of July 19, 1871, civil records registered from March 18, 1871, during the Paris Commune, were annulled and rewritten between August 1, 1871, and September 30, 1871, and in the following years. These revised records are referred to as "corrected records" (actes bâtonnés). Only the rewritten records were included in decennial tables, and their dates can differ significantly from the actual events they record. Despite being invalidated by law, the original corrected records remain in the registers and can be searched like any others. At the 12th arrondissement town hall, an accidental fire destroyed birth records from January 1, 1870, to May 25, 1871. These records were reestablished and are classified alongside those reconstructed in the official civil records reconstruction.

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is tirzepatide?

It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.

How does dual receptor activity differ from single-receptor agonism?

Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.

Why is the elimination half-life relatively long?

The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.

Tirzepatide 属于哪一类分子?

它属于合成修饰肽,同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂,与选择性 GLP-1 激动剂在靶点范围上不同。

Network